O067 Efficacy and safety of interventional therapy of low-flow vascular malformations based on the experience from a single specialist centre

Abstract Introduction To evaluate the efficacy and safety of embolo-sclerotherapy (EST) low-flow vascular malformations (LFVM) in a specialist anomalies centre. Methods All patients with LFVM who underwent EST from 01 January 2015–31 December 2019 were retrospectively reviewed. ESTs performed foam STS 3%, ethanol, coils and/or other substances e.g. triamcinolone. LFVMs grouped according to Puig's classification. The outcome measures treatment effects complications. Continuous variables compared using ANOVA test. Other discrete Chi-squared tests. Differences considered significant at P<0.05. Results A total 207 patients, mean age 32 years (range 1–71 years) included. use was significantly lower for type I (61.8%) others (p<0.001). However, higher (26.5%) treated surgery than Overall, categories different across all types (p<0.001), more discharges Type (52.9%) but failure follow-up II (24.5%) LFVM. complications (14.7%) (p=0.030). doses first procedure (p<0.001) most receiving ≤2 ml. Conclusion particularly sclerotherapy is clinically effective safe especially those lesions. This classification may provide an important guide volume sclerosant required potential success rate. Take-home message